Cytox is developing transformational prognostic technology that may contribute to the assessment of an individual's risk of developing dementias such as Alzheimer's disease.
We are collaborating with academic researchers and the pharmaceutical industry to develop blood-based assays to aid in the development of new, more effective dementia treatments.
We intend to play our part in the fight against Alzheimer's disease and other dementias.
To find out more, follow the links above, or contact us by email.
The development of disease-modifying therapies for Alzheimer's disease is hampered by our lack of understanding of the early pathogenic mechanisms and the lack of validated biomarkers and risk factors. This paper summarises the research showing the role of mTOR in development of Alzheimer's disease and other dementias and outlines a potential new related biomarker test...
Download White Paper